SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease.

Huntington's disease (HD) is a progressive neurological disorder for which there are no disease-modifying treatments. Transcriptional dysregulation is a major molecular feature of HD, which significantly contributes to disease progression. Therefore, the development of histone deacetylase (HDAC) inh...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Michal Mielcarek, Caroline L Benn, Sophie A Franklin, Donna L Smith, Ben Woodman, Paul A Marks, Gillian P Bates
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Public Library of Science (PLoS) 2011-01-01
Colecção:	PLoS ONE
Acesso em linha:	https://doi.org/10.1371/journal.pone.0027746
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!